. Many of these women are of childbearing age and prefer to prevent pregnancy for a variety of reasons, including preventing the possibility of bearing HIV-infected children. Oral contraceptives are one of the most effective means of pregnancy prevention [3]. The coadministration of oral contraceptives with highly active antiretroviral therapy in HIV-infected women is often complicated by significant drug interactions between PIs and the key constituents of common oral contraceptives [1] . A thorough understanding of the drug interactions between PIs and oral contraceptives is crucial in the management of HIV/AIDS treatment in women with child-bearing potential.
Results: ATV/RTV with dose-normalized EE/NGM resulted in geometric mean reductions of 16% in EE peak plasma concentration (C max ), 19% in EE area under the concentrationtime curve for a dosing interval (AUC [t] ) and 37% in EE lowest plasma concentration (C min ), compared with EE 35 µg with NGM in the absence of ATV/RTV. NGM with EE and ATV/RTV 300/100 mg once daily resulted in increases of approximately 68%, 85% and 102% in 17-deacetyl NGM C max , AUC (t) and C min , respectively. Two participants discontinued the study because of adverse events. Conclusions: ATV/RTV with Ortho Tri-Cyclen was welltolerated and reductions in EE were not predicted to decrease contraceptive efficacy if the formulation contained ≥30 µg of EE.
Atazanavir (ATV) is a potent once-daily HIV protease inhibitor (PI) recommended for the treatment of HIVinfected adults and adolescents [1] . Globally, of the 33 million people living with HIV, approximately onehalf are women [2] . Many of these women are of childbearing age and prefer to prevent pregnancy for a variety of reasons, including preventing the possibility of bearing HIV-infected children. Oral contraceptives are one of the most effective means of pregnancy prevention [3] . The coadministration of oral contraceptives with highly active antiretroviral therapy in HIV-infected women is often complicated by significant drug interactions between PIs and the key constituents of common oral contraceptives [1] . A thorough understanding of the drug interactions between PIs and oral contraceptives is crucial in the management of HIV/AIDS treatment in women with child-bearing potential.
The effect of ATV on an oral contraceptive drug was assessed in a previous clinical study in healthy female participants [4] . When ATV (400 mg once daily) was coadministered with Ortho-Novum ® 7/7/7 ( Ortho-McNeil-Janssen Pharmaceuticals, Inc., Raritan, NJ, USA; 0.5 mg norethindrone and 0.035 mg ethinyl estradiol [EE] ), the geometric means of peak plasma concentration (C max ), area under the concentrationtime curve for a dosing interval (AUC [t] ) and lowest plasma concentration (C min ) for EE were increased by 15%, 48% and 91%, respectively, and by 67%, 110% and 262%, respectively, for norethindrone.
Administration of ATV with low-dose ritonavir (RTV) results in increased ATV exposure because of the inhibition of cytochrome P450 (CYP)3A4. The C max and AUC of ATV when coadministered with RTV 100 mg are approximately twofold and threefold 
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higher, respectively, and C min is five-to sevenfold higher than with ATV 300 mg alone (Bristol-Myers Squibb, unpublished data). Because this boosted regimen is more commonly used clinically, the current study was conducted to evaluate the effect of ATV in combination with RTV on the pharmacokinetics (PK) of a combined oral contraceptive containing EE and norgestimate (NGM). Ortho Tri-Cyclen ® and Ortho Tri-Cyclen ® LO (Ortho-McNeil-Janssen Pharmaceuticals, Inc.) were selected for this study because they are among the most commonly prescribed oral contraceptive formulations.
Based on the results of the previous drug interaction study between ATV and the oral contraceptive drug Ortho-Novum 7/7/7, and the fact that RTV increases the concentration of ATV, it was expected that EE exposure would increase in the presence of ATV/RTV [4] . The current study was therefore designed in anticipation of EE exposures with ATV/RTV and Ortho TriCyclen LO (containing EE 25 µg in addition to NGM 0.18/0.215/0.25 mg) being similar to those achieved with Ortho Tri-Cyclen (containing EE 35 µg in addition to NGM 0.18/0.215/0.25 mg) alone.
Since EE and NGM are neither strong inhibitors nor inducers of CYP3A enzymes [5, 6] , coadministration of an oral contraceptive with these components was not expected to significantly affect the exposures to ATV.
Methods
Study design
This was an open-label three-period single-sequence study. Following screening, eligible healthy female participants who had been on a stable regimen of oral contraception for at least 2 months started a 28-day lead-in period to stabilize their contraceptive hormone levels by taking a full cycle of daily Ortho Tri-Cyclen. The menstrual cycles of all participants were synchronized during the lead-in period. Upon acceptable baseline evaluation results (that is, healthy as determined by medical history, physical examination, 12-lead electrocardiography [ECG] and clinical laboratory evaluations), participants returned on day 1 (period 1) to receive a second cycle of daily Ortho Tri-Cyclen (treatment A). With satisfactory safety results (including no adverse events [AEs] or breakthrough bleeding/spotting), participants then began a third cycle on day 29 (period 2) of daily Ortho Tri-Cyclen LO coadministered with ATV/RTV 300/100 mg once daily for 14 days (treatment B). On days 43-49 of period 2, participants took the third phase of Ortho Tri-Cyclen.
During period 1, Ortho Tri-Cyclen was taken by participants at home, except on days 12-14, when they were required to return to the study centre, and the study drugs were administered by the study staff. During period 2, Ortho Tri-Cyclen LO and ATV/RTV were administered by the staff in the study centre on days 29-42; Ortho Tri-Cyclen was taken by participants at home on days 43-49. While participants were housed in the clinical facility, all treatments were dosed in the morning with a light meal. During the furlough period, study staff contacted participants daily to remind them to take their study drug in the morning with a light meal.
Participant eligibility and restrictions
Healthy women between the ages of 18 and 45 years, with a body mass index of 18-32 kg/m 2 , were eligible to participate in the study if they were not nursing or pregnant.
This study was conducted in accordance with Good Clinical Practice and the ethical principles in the Declaration of Helsinki and was approved by the institutional review board/independent ethics committee at each study site. All participants provided written informed consent prior to participation in the study.
During the study, participants received only study medication or medication prescribed by investigators for treatment of specific clinical events. Participants were not permitted to consume alcohol-or caffeinecontaining beverages or grapefruit-containing products, or to smoke for the duration of the study.
PK sample collection and analyses
Blood samples for EE and 17-deacetyl NGM measurements were collected predose (0 h) and at 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, 16 and 24 h after dosing on days 14 and 42; those for ATV and RTV measurements were collected predose (0 h) and at 0.5, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 and 24 h after dosing on day 42. Blood samples consisted of 2 ml each for EE and ATV/RTV analysis, and 4 ml for 17-deacetyl NGM analysis. Samples were centrifuged and stored at -20°C until they were shipped to the laboratory for analysis.
Samples were assayed via liquid chromatography and tandem mass spectrometry. For ATV and RTV, the standard curves were well fitted by a 1/x 2 -weighted quadratic equation over the concentration ranges of 10.0-10,000 and 5.0-5,000 ng/ml, respectively. Values for the between-run and within-run precision for the analytical QC samples were no greater than 1.96% coefficient of variation (CV) and 5.67% CV for ATV, and no greater than 3.02% CV and 4.39% CV for RTV, respectively, with deviations from the nominal concentrations of no more than ±9.60% for ATV and ±12.0% for RTV. For EE, the standard curves were well fitted by a 1/x 2 -weighted linear equation over the concentration range of 2.0-250 pg/ml. Values for the between-run and within-run precision for the analytical QC samples were no greater than 5.57% CV and 10.56% CV, respectively, with deviations from the nominal concentrations of no more than ±1.82%. For 17-deacetyl NGM, the standard curves were well fitted by a 1/x 2 -weighted linear equation over the concentration range of 99.5-4,975 pg/ml. Values for the between-run and within-run precision for the analytical QC samples were no greater than 6.14% CV and 7.21% CV, respectively, with deviations from the nominal concentrations of no more than ±1.28%. The standard curve and QC data indicated that the human plasma assay methods were precise and accurate.
PK parameters were estimated using non-compartmental methods (Kinetica™ version 4.4.1; Thermo Electron Corporation, Philadelphia, PA, USA) [7] . EE and 17-deacetyl NGM C max , time of peak plasma concentration (T max ), C min and AUC (t) were derived from the plasma concentration-time profiles for days 14 and 42, whereas ATV and RTV C max , T max , C min and AUC (t) were derived from the plasma concentrationtime profiles on day 42.
Safety analyses
Analysis of safety was based on medical review of AE reports, vital signs, ECGs, physical examination findings and laboratory results. A physical examination was performed and 12-lead ECG was obtained at the screening visit, days -1 and 28, and prior to study discharge. Clinical laboratory assessments were performed at screening, days -29, -1, predose on days 11 (pregnancy test only), 28, 35 and 43, and on day 50 at study discharge. AE data were obtained by collection of voluntary complaints by the participants and monitoring or questioning of the participant by the study staff, as well as by investigator review of vital signs, ECGs, laboratory and other data.
Statistical analyses
The effect of coadministered ATV/RTV on EE PK was estimated by comparing EE PK parameters from treatment B to treatment A. Because the EE doses were not the same in treatments A and B, the absolute magnitude of the effect was estimated by normalizing EE dose in treatment B (25 µg) to an EE dose of 35 µg. Dose normalization was based on dose linearity according to the product labels for Ortho Tri-Cyclen and Ortho Tri-Cyclen LO [8, 9] .
The results from the comparisons described above were presented as geometric means and ratios of adjusted geometric means and 90% confidence intervals (CIs). These estimates were created by fitting general linear models to log-transformed PK parameters (C max , C min and AUC [t] ) for EE and 17-deacetyl NGM. Factors included in the analyses were treatment as a fixed effect and within-participant measurements as repeated measurements. Point estimates and 90% CIs for differences on the log scale were exponentiated to obtain estimates for ratios of geometric means on the original scale. Treatment A was used as the reference in all comparisons, and no adjustments were made for multiplicity. In addition, PK parameters for all analytes were summarized by treatment.
Based on the assumption that EE C max and AUC (t) are log-normally distributed with interparticipant coefficients of variation of 31% and 27%, respectively, and that the correlation coefficient between two treatment periods was 0.6, as estimated from published data [10] , 14 participants would provide at least 83% and 89% confidence that the estimated ratios of the geometric means for EE C max and AUC (t) , respectively, with or without ATV/RTV, would be within 10% of the true ratios. To allow for dropouts, 20 participants were dosed on day 1 (period 1).
All available data from participants who received study drug and had valid concentration data were included in the PK data set. All available data from enrolled participants were included in the safety data set. All statistical analyses were carried out using SAS/STAT ® version 8.2 (SAS Institute, Inc., Cary, NC, USA).
Results
A total of 20 participants started the lead-in period and 13 completed the study. Dosed participants had a mean age of 28 years (range 19-45), 75% were White, 10% Black and 15% other ethnicity, mean body mass index was 25.3 kg/m 2 (range 18.4-31.5), mean weight was 66.1 kg (range 47.6-91.3) and mean height was 161 cm (range 150-175).
PK analyses
PK analysis for EE EE was rapidly absorbed after the administration of oral contraceptives, either alone or with ATV and RTV. The T max ranged from 1-3 h for both treatments. When Ortho Tri-Cyclen was administered alone (treatment A), the PK parameters for EE at the steady-state were found to be very similar to what have been reported in the literature. The geometric means for EE AUC (t), C max and C min were 1,280 pg•h/ml, 136 pg/ml and 24 pg/ ml, respectively. Contrary to expectations, when Ortho Tri-Cyclen LO was coadministered with ATV and RTV (treatment B), the exposures to EE were significantly reduced. The geometric means for EE AUC (t), C max and C min at the steady-state were 722 pg•h/ml, 81 pg/ml and 11 pg/ml, respectively. Steady-state plasma concentration-time profiles for EE are shown in Figure 1 .
Because of these unexpected results and the different EE doses contained in the two oral contraceptive formulations used in the two treatments, a dose normalization was performed to compare the two treatments and to estimate the magnitude of reduction in EE exposures. This normalization was based on the dose proportionality of EE exposures between the two doses [8, 9] . The results of statistical analyses for EE PK parameters following dose normalization of treatment B are shown in Table 1 . Based on these calculations, coadministration of ATV/RTV 300/100 mg once daily plus EE with NGM was expected to result in geometric mean reductions of 16% in EE C max , 19% in EE AUC (t) and 37% in EE C min , compared with EE with NGM in the absence of ATV/RTV. Figure  2A shows the comparison of EE AUC (t) following dose normalization of treatment B for each individual patient.
PK analysis for 17-deacetyl NGM 17-Deacetyl NGM was analysed as a surrogate for NGM because the serum concentration of NGM generally decreases to below assay detection within 5.0 h of oral administration and is quickly metabolized to 17-deacetyl NGM, which has a pharmacological profile and activity very similar to NGM. Additionally, 17-deacetyl NGM typically appears rapidly in the plasma, with a concentration greatly exceeding its parent compound (35-40-fold). With an elimination half-life of 12-30 h [8], 17-deacetyl NGM is considered to play an important role in contraception. Figure 1 shows the steady-state plasma concentration-time profiles for 17-deacetyl NGM following administration of Ortho Tri-Cyclen alone as well as following the coadministration of Ortho Tri-Cyclen LO with ATV and RTV. Figure 2B shows the comparison of 17-deacetyl NGM AUC (t) for each individual patient. Table 1 shows the statistical analyses comparing 17-deacetyl NGM PK parameters. Coadministration of NGM with EE and ATV/RTV 300/100 mg once daily resulted in increases of approximately 68%, 85% and 102% in 17-deacetyl NGM C max , AUC (t) and C min , respectively.
PK analysis for ATV and RTV ATV exposures (geometric mean [CV%]
) upon coadministration of ATV/RTV 300/100 mg and EE with NGM were 6,779 ng/ml (24%) for C max , 68,712 ng•h/ml (29%) for AUC (t) and 1,739 ng/ml (44%) for C min . The RTV exposures (geometric mean [CV%]) upon coadministration of ATV/RTV 300/100 mg and EE with NGM were 1,480 ng/ml (41%) for C max , 10,471 ng•h/ml (32%) for AUC (t) , and 69 ng/ml (62%) for C min .
Safety assessment
The most frequent AEs in treatment A were headache (16%) and diarrhoea (11%). In treatment B the most frequent AEs were headache (38%), rash (38%) and vomiting (19%). All AEs were reported as mild or moderate in intensity, and there was a somewhat higher rate of AEs in treatment B compared with treatment A (vomiting, headache and abdominal pain); however, abdominal cramps, nausea or metrorrhagia were not overrepresented in treatment B relative to the lead-in period or treatment A.
There were no deaths or serious AEs in this study. Seven participants discontinued treatment, two of whom discontinued because of AEs. One participant discontinued prior to treatment A because of a urinary tract infection that was judged by the investigator as unlikely to be related to treatment and mild in intensity. Another participant discontinued because of urticaria that was judged by the investigator as probably related to treatment B. Other reasons for discontinuation included poor/non-compliance (n=1), withdrawal of informed consent (n=3) and schedule conflict (n=1).
All 16 (100%) participants with safety data had expected and benign total bilirubin marked abnormalities that are known to be associated with ATV following administration of treatment B. Of these 16 participants, 3 (18.8%) also had direct bilirubin elevation. The total bilirubin elevation ranged from 1.5-9.4 mg/dl (System International [SI] conversion 25.7-160.7 mol/l), and had returned to normal levels by study discharge or follow-up in all but one participant in whom the total bilirubin had reduced at study discharge to 2.3 mg/dl (SI conversion 39.3 mol/l), and who was not required to return for a follow-up visit. One other participant had elevations in both alanine aminotransferase and aspartate aminotransferase without elevations in direct bilirubin or alkaline phosphatase and with mild elevation of indirect bilirubin. These laboratory abnormalities had returned to the normal range when the participant was discharged from the study following administration of treatment B.
Discussion
In this study, ATV/RTV decreased exposures of EE and increased exposures of 17-deacetyl NGM, the active metabolite used as a surrogate for NGM, relative to EE and NGM exposures in the absence of ATV/RTV.
The effect of the ATV/RTV combination on EE is different from that observed when ATV was given in the absence of RTV [4] . When ATV 400 mg was coadministered once daily with Ortho-Novum 7/7/7, it increased the EE exposure, whereas in this study, when ATV was boosted with RTV, EE exposure was decreased.
The precise mechanism of action resulting in the reduction of EE observed in this study is unclear. Following oral administration, EE is subject to extensive first-pass metabolism, both in the gut as well as in the liver. Sulphate conjugation in the gut contributes to approximately 60% of the first-pass effect. Once absorbed, the major metabolic pathway involves hydroxylation by CYP3A4 and glucuronidation by uridine diphosphate glucuronosyltransferase (UGT) [11, 12] . ATV is an inhibitor of CYP3A4 and UGT1A1, which are both involved in the metabolism of EE [4, 13] . The increased exposure of EE when coadministered with ATV is likely caused by the inhibition of these enzymes. A similar observation has been reported for indinavir, another PI that inhibits UGT1A1, when given with EE in the absence of RTV [14] . The EE AUC increased by approximately 22%.
The effect of RTV at a high dose (500 mg twice daily) on EE is a decrease in the C max and AUC of EE by 32% and 41%, respectively, possibly through enzymatic induction occurring after chronic administration [15] . It has been shown that RTV activates the pregnane X receptor, which induces the sulphotransferases involved in the major elimination pathway of EE [16, 17] . The inductive role of RTV for EE metabolism is also suggested by the report that Kaletra ® (Abbott Laboratories, Abbott Park, IL, USA), in which a low dose of RTV is coformulated with lopinavir, decreases EE exposure [18] .
The results from this study showed that the net effect of the ATV/RTV combination on EE is increased clearance, although the specific metabolic enzymatic system could not be identified. Because sulphation is one of the major elimination pathways for EE, and UGT1A1 was suppressed under ATV/RTV coadministration (as evidenced by the benign increases in bilirubin levels in all participants), the increased clearance is suspected because of an induction of sulphotransferases [13, 16, 19] . Additionally, it has been reported that CYP2C9 might be involved in the metabolism of EE [20] , and thus the induction of CYP2C9 by RTV might also play a role in the reduction of EE exposures [21] .
In order to examine whether the reduced EE exposure resulting from ATV/RTV coadministration would still be able to maintain an exposure level comparable to currently marketed low-EE oral contraceptive drugs (such as Ortho Tri-Cyclen LO) administered alone, a post hoc comparison was conducted, comparing the PK parameters from treatment B normalized to an EE dose of 35 µg to those from treatment A normalized to an EE dose of 25 µg. This post hoc analysis was based on dose linearity indicated by PK parameters reported in the product labels. In this analysis, the C max and AUC (t) of EE following administration of an oral contraceptive containing 35 µg of EE (as in Ortho Cyclen and Ortho Tri-Cyclen) with ATV/RTV 300/100 mg once daily were projected to be comparable to those following the administration of a low-dose oral contraceptive containing 25 µg of EE, such as Ortho Tri-Cyclen LO, in the absence of ATV/ RTV. The bounds of the 90% CI for EE AUC (t) geometric mean ratio were contained entirely within the 0.80-1.25 no-effect range.
When considering the variability, the 90% CI of the geometric mean ratio (comparing the EE AUC (t) from a combined oral contraceptive with 35 µg EE in the presence of ATV/RTV versus that of 35 µg EE alone) is 0.75-0.87 (Table 1) , which indicates, with 90% confidence, that EE AUC when coadministered with ATV/ RTV will lead to no more than 25% reduction in geometric mean of EE AUC from the 35 µg EE regimen. Thus, when coadministered with ATV/RTV, combined oral contraceptives containing ≥30 µg EE would deliver ≥22.5 µg EE.
Combined oral contraceptives with EE doses of ≥20 µg have been well-studied, and have shown consistent efficacy compared with those of currently marketed products [22, 23] . It has also been shown that excellent cycle control and tolerability were achieved in women switching from oral contraceptives containing 30-35 µg EE to Ortho Tri-Cyclen LO [24] . Our results suggest that women who are taking oral contraceptives containing ≥30 µg of EE and an RTV-boosted ATV regimen are likely to be able to maintain EE exposures at clinically sufficient levels.
The effect of the ATV/RTV combination on the PK of the progestin component of oral contraceptives was similar to that observed in the previous study when ATV was given in the absence of RTV [4] . Although the specific enzymes involved in the oxidative and phase 2 metabolism of 17-deacetyl NGM are unclear, it is possible that the metabolic pathways are similar between norethindrone and 17-deacetyl NGM. The increased exposures might largely be caused by ATV, via inhibition of UGT1A1. Low-dose RTV by itself has been shown not to affect norethindrone [25] .
The clinical concerns related to the increase in NGM metabolite levels are difficult to define because NGM is regarded as relatively specific for the progestin receptor. The contributions of progestin versus androgenic effects in general among progestational agents are difficult to assess in terms of risk for venous thrombosis, but this risk should be noted. Androgenic effects observed with earlier generation progestins include adverse lipid profile, insulin resistance and acne [26] . Any association between progestins and thromboembolic events is less clear, and there is conflicting evidence as to whether NGM-containing products might carry an increased risk of thromboembolism [27, 28] . Thus, participants with heightened risk factors for insulin resistance or thromboembolism, such as smoking, age, obesity or family history, should be carefully evaluated when considering coadministration of progestin-containing oral contraceptives with ATV/RTV 300/100 mg.
Because the contraceptive efficacy of Ortho TriCyclen is mostly dependent on adequate progestin levels [29] , coadministration of ATV/RTV 300/100 mg, EE 35 µg and a standard cyclic dosage of NGM of 0.18/0.215/0.25 mg, is predicted to result in an overall contraceptive effect as efficacious as standard Ortho TriCyclen LO (EE 25 µg and NGM 0.18/0.215/0.25 mg) in the absence of ATV/RTV.
The ATV exposures observed in this study appear slightly higher than historical data obtained from healthy volunteers: the geometric mean value for C max was 11% higher (6,779 ng/ml in this study when ATV/RTV was coadministered with EE and NGM versus 6,129 ng/ml seen historically when ATV/RTV was given alone), and AUC (0-24) was approximately 20% higher (68,712 ng•h/ml in this study versus 57,039 ng•h/ml seen historically) [30] . However, the differences are not considered clinically significant as the exposure levels remained within the safety range observed in healthy participants and ATV exposures are typically lower in HIV-infected patients than healthy individuals [30] . It is not clear whether the differences were caused by the gender profile (only female participants were included in this study, whereas males predominately participated in other studies) or the effect of EE with NGM, as the study was conducted without an ATV/RTV alone withinstudy control arm. The differences might also reflect interstudy assay variations. Further evaluation on gender effect is planned to help determine the cause of the difference.
Conclusions
In conclusion, ATV/RTV with Ortho Tri-Cyclen LO (EE 25 µg with NGM 0.18/0.215/0.25 mg) appears to be safe and well-tolerated. Reductions of approximately 20% in EE levels were observed; however, the reductions in EE observed in this study would not be predicted to decrease contraceptive efficacy, because the exposure to the active component progestin is increased. Increasing the EE component to 30-35 µg (for example, Ortho Tri-Cyclen) when coadministered with ATV/RTV might be desirable to minimize breakthrough bleeding. Progestin levels were increased when ATV/RTV was combined with Ortho Tri-Cyclen LO, with a potential for androgenic side effects. An oral contraceptive agent containing ≥30 µg of EE might be an option for HIV-infected women receiving ATV/ RTV 300/100 mg once daily.
